Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
Sarah C J Jorgensen, Christopher L.Y. Tse, Lisa Burry, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2020) Vol. 40, Iss. 8, pp. 843-856
Open Access | Times Cited: 195

Showing 1-25 of 195 citing articles:

Pharmaco-Immunomodulatory Therapy in COVID-19
John G. Rizk, Kamyar Kalantar‐Zadeh, Mandeep R. Mehra, et al.
Drugs (2020) Vol. 80, Iss. 13, pp. 1267-1292
Open Access | Times Cited: 275
COVID-19: Characteristics and Therapeutics
Rameswari Chilamakuri, Saurabh Agarwal
Cells (2021) Vol. 10, Iss. 2, pp. 206-206
Open Access | Times Cited: 259
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Sairaj Satarker, Antriya Annie Tom, Roshitha Ann Shaji, et al.
Postgraduate Medicine (2020) Vol. 133, Iss. 5, pp. 489-507
Open Access | Times Cited: 147
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models
Ornella Urzì, Roberta Gasparro, Elisa Costanzo, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12046-12046
Open Access | Times Cited: 39
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
Mona Sadat Mirtaleb, Amir Hossein Mirtaleb, Hassan Nosrati, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 138, pp. 111518-111518
Open Access | Times Cited: 60
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
Ian M. Catlett, Yanhua Hu, Lu Gao, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 6, pp. 2010-2020.e8
Closed Access | Times Cited: 56
Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis
Partha Biswas, Mohammad Mehedi Hasan, Dipta Dey, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 42, pp. 59570-59593
Open Access | Times Cited: 55
JAK inhibitors and COVID-19
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e002838-e002838
Open Access | Times Cited: 50
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
Reza Elahi, Parsa Karami, Amir Hossein Heidary, et al.
International Immunopharmacology (2022) Vol. 105, pp. 108536-108536
Open Access | Times Cited: 43
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms
Sawsan Aboul‐Fotouh, Ahmed N. Mahmoud, Esraa M. Elnahas, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 29
An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor
Oscar E. Reyes Gaido, Nikoleta Pavlaki, Jonathan Granger, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 701
Closed Access | Times Cited: 27
The crucial regulatory role of type I interferon in inflammatory diseases
Ling Ji, Tianle Li, Huimin Chen, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 26
Omicron variant evolution on vaccines and monoclonal antibodies
Michela Sabbatucci, Antonio Vitiello, Salvatore Clemente, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 4, pp. 1779-1788
Open Access | Times Cited: 25
Toward an Improved Electrocatalytic Determination of Immunomodulator COVID Medication Baricitinib Using Multiwalled Carbon Nanotube Nickel Hybrid
Enas E. Abbas, Ahmed Salah, Maha A. Hegazy, et al.
ACS Applied Bio Materials (2024) Vol. 7, Iss. 6, pp. 3865-3876
Closed Access | Times Cited: 7
Baricitinib: From Rheumatoid Arthritis to COVID‐19
Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, et al.
The Journal of Clinical Pharmacology (2021) Vol. 61, Iss. 10, pp. 1274-1285
Open Access | Times Cited: 54
Potential Effects of Coronaviruses on the Liver: An Update
Xinyi Wang, Jianyong Lei, Zhihui Li, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 52
Kidney injury in COVID-19 patients, drug development and their renal complications: Review study
Zeynab Mohamadi Yarijani, Houshang Najafi
Biomedicine & Pharmacotherapy (2021) Vol. 142, pp. 111966-111966
Open Access | Times Cited: 41
Blocking TNF signaling may save lives in COVID-19 infection
Vitaly Ablamunits, Christopher Lepsy
Molecular Biology Reports (2022) Vol. 49, Iss. 3, pp. 2303-2309
Open Access | Times Cited: 31
Identification of antiviral phytochemicals from cranberry as potential inhibitors of SARS-CoV-2 main protease (Mpro)
Jisha Pillai U, L. Cherian, Khushman Taunk, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129655-129655
Closed Access | Times Cited: 6
Repositioning of baricitinib for management of memory impairment in ovariectomized/D-galactose treated rats: A potential role of JAK2/STAT3-PI3K/AKT/mTOR signaling pathway
Merhan O. Hindam, Lamiaa A. Ahmed, Nesrine S. El Sayed, et al.
Life Sciences (2024) Vol. 351, pp. 122838-122838
Closed Access | Times Cited: 6
Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management
Sukhbir Singh, Neha Tiwary, Neelam Sharma, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 248-248
Open Access | Times Cited: 5
Role of monoclonal antibody drugs in the treatment of COVID-19
Claudio Ucciferri, Jacopo Vecchiet, Katia Falasca
World Journal of Clinical Cases (2020) Vol. 8, Iss. 19, pp. 4280-4285
Open Access | Times Cited: 40
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
Milo Gatti, Eleonora Turrini, Emanuel Raschi, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 738-738
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top